Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival
Chia-Chi Chen, Ching-Ting Wei, Chin-Feng Hsuan, Teng-Hung Yu, Wei-Chin Hung, Cheng-Ching Wu, Thung-Lip Lee, Wei-Hua Tang, Fu-Mei Chung, Yau-Jiunn Lee, Chia-Chang Hsu · 2025
Read Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival by Chia-Chi Chen, Ching-Ting Wei, Chin-Feng Hsuan, Teng-Hung Yu, Wei-Chin Hung, Cheng-Ching Wu, Thung-Lip Lee, Wei-Hua Tang, Fu-Mei Chung, Yau-Jiunn Lee, Chia-Chang Hsu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717811.txt.
Description
A cell-cycle protein called MYBL2 shows up often in cancers, and Chia-Chi Chen and co-authors ask whether its level in liver tumors predicts patient survival. Their 2025 study covers 88 liver cancer patients who had surgery between 2023 and 2025. Tumor samples were stained to score how much of the protein each one carried.
Patients with high MYBL2 in their tumors died sooner than those with low levels, and the protein's score tracked survival in a graded way. On its own it held up as a risk signal, though it lost that standing once other factors joined the model. The authors propose MYBL2 as a candidate marker for prognosis and a possible drug target. They call for work on how it drives tumor growth.
Catalog record
| CREATOR | Chia-Chi Chen, Ching-Ting Wei, Chin-Feng Hsuan, Teng-Hung Yu, Wei-Chin Hung, Cheng-Ching Wu, Thung-Lip Lee, Wei-Hua Tang, Fu-Mei Chung, Yau-Jiunn Lee, Chia-Chang Hsu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |